Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.56 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25124534 | 0.85 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL31430630 | 0.80 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2060733 | 0.80 | ALDH1A1 (0.61) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL25989651 | 0.78 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL6635089 | 0.78 | MEN1 (0.50) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2420144 | 0.78 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL15172875 | 0.78 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL11443651 | 0.78 | MEN1 (0.62) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL29362134 | 0.78 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10173135 | 0.76 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367714-B2 | Cannabinoid receptor targeted agent | VANDERBILT UNIVERSITY (US) | 2013-02-05 | — | — | US | disclosed |
| US-8323621-B2 | site-directed delivery of contrast agent; brain or breast cancer; 1,4,7,10 tetraazacyclododecane having variable chelating ions, phosphoester chains, and light harvesting moieties for changing imaging methods; conjugated to high affinity PBR ligand PK11195; bound to a PVA or a PEG delivery vehicle | VANDERBILT UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8323621-B2 | site-directed delivery of contrast agent; brain or breast cancer; 1,4,7,10 tetraazacyclododecane having variable chelating ions, phosphoester chains, and light harvesting moieties for changing imaging methods; conjugated to high affinity PBR ligand PK11195; bound to a PVA or a PEG delivery vehicle | VANDERBILT UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20090105128-A1 | CANNABINOID RECEPTOR TARGETED AGENT | VANDERABILT UNIVERSITY | 2009-04-23 | — | — | US | disclosed |
| US-20080241873-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | BORNHOP DARRYL J | 2008-10-02 | — | — | US | disclosed |
| US-20080241074-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | VANDERBILT UNIVERSITY | 2008-10-02 | — | — | US | disclosed |
| US-20080241074-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | VANDERBILT UNIVERSITY | 2008-10-02 | — | — | US | disclosed |
| US-7338651-B2 | Multi-use multimodal imaging chelates | TEXAS TECH UNIVERSITY SYSTEM (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105128-A1 | CANNABINOID RECEPTOR TARGETED AGENT | CNR1, CNR2, NPY1R | RAB9A 501/4885NPC1 495/4885SMN1; SMN2 4547/4885 |
| US-20080241074-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | PCNA, CLTC, CLTB | RAB9A 3729/4885NPC1 3025/4885SMN1; SMN2 4260/4885 |
| US-20080241873-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | PCNA, CLTC, CLTB | RAB9A 3729/4885NPC1 3025/4885SMN1; SMN2 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.